{"protocolSection": {"identificationModule": {"nctId": "NCT01125514", "orgStudyIdInfo": {"id": "CSPP100A2255"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "A Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure", "officialTitle": "A Single-blind, Multiple Dose, Placebo-controlled, Double Dummy Study to Investigate the Pharmacodynamic and Pharmacokinetic Interaction Between Aliskiren and Furosemide in Patients With Heart Failure"}, "statusModule": {"statusVerifiedDate": "2012-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-05"}, "primaryCompletionDateStruct": {"date": "2011-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-05-17", "studyFirstSubmitQcDate": "2010-05-17", "studyFirstPostDateStruct": {"date": "2010-05-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-08-09", "resultsFirstSubmitQcDate": "2012-08-09", "resultsFirstPostDateStruct": {"date": "2012-09-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2012-08-09", "lastUpdatePostDateStruct": {"date": "2012-09-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study assessed the interaction between single and multiple doses of aliskiren (150 mg and 300 mg) and furosemide (60 mg) in patients with heart failure."}, "conditionsModule": {"conditions": ["Heart Failure"], "keywords": ["Heart failure,", "aliskiren,", "furosemide,", "diuretic efficacy,", "interaction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "NON_RANDOMIZED", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Furosemide 60 mg", "type": "EXPERIMENTAL", "description": "Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.", "interventionNames": ["Drug: Furosemide 60 mg", "Drug: Placebo for Aliskiren"]}, {"label": "Furosemide 60 mg + Aliskiren 150 mg", "type": "EXPERIMENTAL", "description": "Treatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.", "interventionNames": ["Drug: Aliskiren 150 mg", "Drug: Furosemide 60 mg", "Drug: Placebo for Aliskiren"]}, {"label": "Furosemide 60 mg + Aliskiren 300 mg", "type": "EXPERIMENTAL", "description": "Treatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.", "interventionNames": ["Drug: Furosemide 60 mg", "Drug: Placebo for Aliskiren", "Drug: Aliskiren 300 mg"]}], "interventions": [{"type": "DRUG", "name": "Aliskiren 150 mg", "description": "Aliskiren 150 mg tablet", "armGroupLabels": ["Furosemide 60 mg + Aliskiren 150 mg"]}, {"type": "DRUG", "name": "Furosemide 60 mg", "description": "Furosemide 60 mg commercially-available tablets", "armGroupLabels": ["Furosemide 60 mg", "Furosemide 60 mg + Aliskiren 150 mg", "Furosemide 60 mg + Aliskiren 300 mg"]}, {"type": "DRUG", "name": "Placebo for Aliskiren", "description": "Matching placebo for aliskiren 150 mg and 300 mg", "armGroupLabels": ["Furosemide 60 mg", "Furosemide 60 mg + Aliskiren 150 mg", "Furosemide 60 mg + Aliskiren 300 mg"]}, {"type": "DRUG", "name": "Aliskiren 300 mg", "description": "Aliskiren 300 mg tablet", "armGroupLabels": ["Furosemide 60 mg + Aliskiren 300 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Diuretic Efficacy Index 1 for Sodium Excretion", "description": "Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 4 hour urine collection.", "timeFrame": "0 to 4 hours"}, {"measure": "Diuretic Efficacy Index 1 for Sodium Excretion", "description": "Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 24 hour urine collection.", "timeFrame": "0 to 24 hours"}, {"measure": "Diuretic Efficacy Index 2 for Water Excretion", "description": "Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction urine collection.", "timeFrame": "0 to 4 hours"}, {"measure": "Diuretic Efficacy Index 2 for Water Excretion", "description": "Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction and for the total 0 to 24 hour urine collection.", "timeFrame": "0 to 24 hours"}], "secondaryOutcomes": [{"measure": "Plasma Pharmacokinetics (PK) of Furosemide: Area Under the Plasma Concentration-time Curve (AUC)", "description": "Pharmacokinetic (PK) parameters were determined from the plasma concentration time profile of furosemide using a non-compartmental method:\n\nAUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval\n\nAUC (0-24): Area under the plasma concentration-time curve from time zero to 24 hours\n\nAUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. AUClast was calculated as the sum of linear trapezoids using non-compartmental analysis.\n\nAUCinf: Area under the plasma concentration-time curve from time zero to infinity. AUCinf was calculated by adding AUClast and the value obtained from dividing the last measurable plasma concentration by \u03bbz, where \u03bbz was determined from automated linear regression of the last three time points with non-zero concentrations in the terminal phase of the log-transformed concentration-time profile", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose"}, {"measure": "Plasma Pharmacokinetics (PK) of Furosemide: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)", "description": "Cmax,ss was directly determined from the raw plasma concentration-time data.", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose"}, {"measure": "Plasma Pharmacokinetics (PK) of Furosemide: Time to Reach the Maximum Concentration After Drug Administration (Tmax)", "description": "Tmax was directly determined from the raw plasma concentration-time data.", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose"}, {"measure": "Plasma Pharmacokinetics (PK) of Furosemide: Average Steady State Plasma Concentration During Multiple Dosing (Cav,ss)", "description": "The average steady-state drug concentration in the plasma, blood, serum, or other body fluids during multiple dosing \\[amount x volume-1\\]. This was estimated as AUC\u03c4/\u03c4", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose"}, {"measure": "Plasma Pharmacokinetics (PK) of Furosemide: Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin, ss)", "description": "The minimum observed steady-state drug concentration in the plasma, blood, serum, or other body fluids at the end of the dosing interval during multiple dosing \\[amount x volume-1\\]", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24 hours post dose"}, {"measure": "Urine Pharmacokinetics (PK) of Furosemide: Amount of Drug Excreted Into the Urine From Time Zero to 24 Hours After Administration (Ae0-24)", "description": "The area under the plasma (or serum or blood) concentration-time curve from time zero to 24 h \\[mass \u00d7 time \u00d7 volume-1\\]", "timeFrame": "0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose"}, {"measure": "Urine Pharmacokinetics (PK) of Furosemide: Renal Clearance (CLR)", "description": "The renal clearance of drug \\[volume x time-1\\]", "timeFrame": "0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose"}, {"measure": "Creatinine Clearance", "description": "Creatinine clearance= (Urine creatinine/Serum creatinine) x (Urine volume/(24\\*60)).", "timeFrame": "0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose"}, {"measure": "Urine Sodium and Potassium Excretion Per Treatment at 4 Hours Postdose", "description": "Urine was collected 4 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 4 hours.", "timeFrame": "4 hours postdose"}, {"measure": "Urine Sodium and Potassium Excretion Per Treatment at 8 Hours Postdose", "description": "Urine was collected 8 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 8 hours.", "timeFrame": "8 hours postdose"}, {"measure": "Urine Sodium and Potassium Excretion Per Treatment at 12 Hours Postdose", "description": "Urine was collected 12 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 12 hours.", "timeFrame": "12 hours postdose"}, {"measure": "Urine Sodium and Potassium Excretion Per Treatment at 24 Hours Postdose", "description": "Urine was collected 24 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 24 hours.", "timeFrame": "24 hours postdose"}, {"measure": "Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "Sitting blood pressure was measured three times at 1 to 2-minute intervals. The mean of the three sitting blood pressure measurements was used as the average of the sitting office blood pressure. The msSBP and msDBP data were analyzed using a mixed effect model with fixed effects from treatment and treatment\\*time; random effect from patients and predose as covariate.", "timeFrame": "0.5 hour pre-dose, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose."}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Systolic or diastolic heart failure, diagnosed with either NYHA functional class II to III at least 3 months prior to screening and on stable medication for at least 12 weeks.\n* Patients must have met either of the criteria at screening:\n* Documented left ventricular ejection fraction (LVEF) greater than 20% but lower than 40% OR\n* Patients with a documented LVEF greater than 40% and with a history of NT-pro-BNP\\> 400pg/mL (or BNP \\> 100pg/mL) within 12 months of screening.\n\nExclusion Criteria:\n\n* Treatment with Angiotensin Receptor Blockers (ARBs), aldosterone receptor antagonists and diuretics (other than furosemide) within 3 weeks of first dose and during the study. Beta blockers were permitted provided the dose was stable for at least 3 weeks before the first dose and remains so throughout the study.\n* Hypertrophic cardiomyopathy (HCMP).\n* If a subject is currently treated with furosemide, the dose must be stable for at least 3 weeks before the first dose and the dose must not exceed 60 mg daily\n* Stable heart failure requiring treatment with both an ACE inhibitor and an ARB or Current acute decompensated heart failure.\n* Mean sitting systolic blood pressure \u2265160 mmHg and/or mean sitting diastolic blood pressure \u2265 100mmHg and/or secondary forms of hypertension.\n* Persistent sitting systolic blood pressure \\<90 mmHg.\n* History of angioedema.\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Furosemide (Fu) /Fu+Aliskiren(Alis)150mg/fu+Alis 300mg", "description": "Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.\n\nTreatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.\n\nTreatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.\n\nDay 28, no study treatment."}], "periods": [{"title": "Treatment Period 1 (Day 1 - Day 7)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Randomized and safety population", "numSubjects": "37"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Administrative problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "Treatment Period 2 (Day 8 - Day 17)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}]}, {"type": "Pharmacokinetic (PK) Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "33"}]}, {"type": "Pharmacodynamics (PD) Analysis Set", "achievements": [{"groupId": "FG000", "numSubjects": "33"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "32"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}, {"title": "Treatment Period2(Day9-Day27) and Day 28", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "32"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "28"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Furosemide (Fu) /Fu+Aliskiren(Alis)150mg/fu+Alis 300mg", "description": "Treatment period 1 (Day 1 to Day 7): All eligible patients received 60 mg furosemide, 150 mg placebo of aliskiren, and 300 mg placebo aliskiren once daily.\n\nTreatment Period 2 (Day 8 to day 17): Patients received 60 mg furosemide, 150 mg aliskiren and 300 mg placebo once daily.\n\nTreatment Period 3 (Day 18 to day 27): Patients received 60 mg furosemide, 300 mg aliskiren and 150 mg placebo of aliskiren once daily.\n\nDay 28, no study treatment."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "37"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "59.6", "spread": "11.90"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "34"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Diuretic Efficacy Index 1 for Sodium Excretion", "description": "Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 4 hour urine collection.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/mg", "timeFrame": "0 to 4 hours", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg+ Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.185", "spread": "4.4568"}, {"groupId": "OG001", "value": "12.122", "spread": "6.2867"}, {"groupId": "OG002", "value": "13.453", "spread": "8.3524"}, {"groupId": "OG003", "value": "12.858", "spread": "6.1040"}]}]}]}, {"type": "PRIMARY", "title": "Diuretic Efficacy Index 1 for Sodium Excretion", "description": "Efficacy of furosemide for sodium excretion (efficacy index 1) was defined by dividing urinary sodium excretion by the urinary excretion of furosemide. Diuretic index 1 for sodium was calculated for the for the total 0 to 24 hour urine collection.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/mg", "timeFrame": "0 to 24 hours", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg+ Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10.775", "spread": "5.2486"}, {"groupId": "OG001", "value": "13.264", "spread": "6.3535"}, {"groupId": "OG002", "value": "13.364", "spread": "6.1511"}, {"groupId": "OG003", "value": "14.747", "spread": "6.3531"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Pharmacokinetics (PK) of Furosemide: Area Under the Plasma Concentration-time Curve (AUC)", "description": "Pharmacokinetic (PK) parameters were determined from the plasma concentration time profile of furosemide using a non-compartmental method:\n\nAUCtau: Area under the plasma concentration-time curve from time zero to the end of the dosing interval\n\nAUC (0-24): Area under the plasma concentration-time curve from time zero to 24 hours\n\nAUClast: Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration. AUClast was calculated as the sum of linear trapezoids using non-compartmental analysis.\n\nAUCinf: Area under the plasma concentration-time curve from time zero to infinity. AUCinf was calculated by adding AUClast and the value obtained from dividing the last measurable plasma concentration by \u03bbz, where \u03bbz was determined from automated linear regression of the last three time points with non-zero concentrations in the terminal phase of the log-transformed concentration-time profile", "populationDescription": "All patients who received at least one dose of study drug and had evaluable Pharmacokinetic (PK) data with no major protocol deviation in at least one period were included in the PK analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "h*ng/mL", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "AUCtau", "categories": [{"measurements": [{"groupId": "OG000", "value": "5217", "spread": "1996.7"}, {"groupId": "OG001", "value": "4255", "spread": "1390.6"}, {"groupId": "OG002", "value": "4638", "spread": "1532.9"}, {"groupId": "OG003", "value": "4218", "spread": "1469.3"}]}]}, {"title": "AUC", "categories": [{"measurements": [{"groupId": "OG000", "value": "5217", "spread": "1996.7"}, {"groupId": "OG001", "value": "4255", "spread": "1390.6"}, {"groupId": "OG002", "value": "4638", "spread": "1532.9"}, {"groupId": "OG003", "value": "4218", "spread": "1469.3"}]}]}, {"title": "AUClast", "categories": [{"measurements": [{"groupId": "OG000", "value": "5154", "spread": "1999.2"}, {"groupId": "OG001", "value": "4207", "spread": "1387.5"}, {"groupId": "OG002", "value": "4535", "spread": "1531.6"}, {"groupId": "OG003", "value": "4130", "spread": "1525.4"}]}]}, {"title": "AUCinf", "categories": [{"measurements": [{"groupId": "OG000", "value": "5420", "spread": "2005.2"}, {"groupId": "OG001", "value": "4559", "spread": "1387.4"}, {"groupId": "OG002", "value": "4783", "spread": "1611.7"}, {"groupId": "OG003", "value": "4381", "spread": "1578.3"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Pharmacokinetics (PK) of Furosemide: Observed Maximum Plasma Concentration Following Drug Administration at Steady State (Cmax, ss)", "description": "Cmax,ss was directly determined from the raw plasma concentration-time data.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacokinetic (PK) data with no major protocol deviation in at least one period were included in the PK analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1702", "spread": "708.66"}, {"groupId": "OG001", "value": "1326", "spread": "518.15"}, {"groupId": "OG002", "value": "1317", "spread": "542.73"}, {"groupId": "OG003", "value": "1180", "spread": "404.92"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Pharmacokinetics (PK) of Furosemide: Time to Reach the Maximum Concentration After Drug Administration (Tmax)", "description": "Tmax was directly determined from the raw plasma concentration-time data.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Hours", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.500", "lowerLimit": "1.00", "upperLimit": "3.00"}, {"groupId": "OG001", "value": "1.500", "lowerLimit": "0.500", "upperLimit": "3.00"}, {"groupId": "OG002", "value": "1.500", "lowerLimit": "1.00", "upperLimit": "4.00"}, {"groupId": "OG003", "value": "2.00", "lowerLimit": "0.500", "upperLimit": "3.00"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Pharmacokinetics (PK) of Furosemide: Average Steady State Plasma Concentration During Multiple Dosing (Cav,ss)", "description": "The average steady-state drug concentration in the plasma, blood, serum, or other body fluids during multiple dosing \\[amount x volume-1\\]. This was estimated as AUC\u03c4/\u03c4", "populationDescription": "All subjects with evaluable pharmacokinetic parameter data with no exclusion flags and no major protocol deviations.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "217.4", "spread": "83.196"}, {"groupId": "OG001", "value": "177.3", "spread": "57.942"}, {"groupId": "OG002", "value": "193.2", "spread": "63.872"}, {"groupId": "OG003", "value": "175.8", "spread": "61.219"}]}]}]}, {"type": "SECONDARY", "title": "Plasma Pharmacokinetics (PK) of Furosemide: Lowest Plasma Concentration Observed During a Dosing Interval at Steady State (Cmin, ss)", "description": "The minimum observed steady-state drug concentration in the plasma, blood, serum, or other body fluids at the end of the dosing interval during multiple dosing \\[amount x volume-1\\]", "populationDescription": "All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg+ Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "20.42", "spread": "25.558"}, {"groupId": "OG001", "value": "20.03", "spread": "23.780"}, {"groupId": "OG002", "value": "19.80", "spread": "29.258"}, {"groupId": "OG003", "value": "16.70", "spread": "20.868"}]}]}]}, {"type": "SECONDARY", "title": "Urine Pharmacokinetics (PK) of Furosemide: Amount of Drug Excreted Into the Urine From Time Zero to 24 Hours After Administration (Ae0-24)", "description": "The area under the plasma (or serum or blood) concentration-time curve from time zero to 24 h \\[mass \u00d7 time \u00d7 volume-1\\]", "populationDescription": "All patients who received at least one dose of study drug and had evaluable PK data with no major protocol deviation in at least one period were included in the PK analysis set", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg", "timeFrame": "0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg+ Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "18.61", "spread": "5.9012"}, {"groupId": "OG001", "value": "15.08", "spread": "3.9613"}, {"groupId": "OG002", "value": "14.98", "spread": "4.5264"}, {"groupId": "OG003", "value": "13.63", "spread": "4.5134"}]}]}]}, {"type": "SECONDARY", "title": "Urine Pharmacokinetics (PK) of Furosemide: Renal Clearance (CLR)", "description": "The renal clearance of drug \\[volume x time-1\\]", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacodynamic (PD) data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L/h", "timeFrame": "0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.808", "spread": "1.3567"}, {"groupId": "OG001", "value": "3.841", "spread": "1.4321"}, {"groupId": "OG002", "value": "3.519", "spread": "1.3592"}, {"groupId": "OG003", "value": "3.561", "spread": "1.4458"}]}]}]}, {"type": "SECONDARY", "title": "Creatinine Clearance", "description": "Creatinine clearance= (Urine creatinine/Serum creatinine) x (Urine volume/(24\\*60)).", "populationDescription": "All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/min", "timeFrame": "0 to 4, 4 to 8, 8 to 12 and 12 to 24 hours post dose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "29"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "104.745", "spread": "38.2884"}, {"groupId": "OG001", "value": "109.657", "spread": "30.0667"}, {"groupId": "OG002", "value": "103.841", "spread": "28.2845"}, {"groupId": "OG003", "value": "105.304", "spread": "25.4076"}]}]}]}, {"type": "SECONDARY", "title": "Urine Sodium and Potassium Excretion Per Treatment at 4 Hours Postdose", "description": "Urine was collected 4 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 4 hours.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol", "timeFrame": "4 hours postdose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "Sodium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "113.992", "spread": "47.5976"}, {"groupId": "OG001", "value": "104.031", "spread": "49.5036"}, {"groupId": "OG002", "value": "98.691", "spread": "55.0495"}, {"groupId": "OG003", "value": "93.341", "spread": "43.9419"}]}]}, {"title": "Potassium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "24.555", "spread": "11.9749"}, {"groupId": "OG001", "value": "19.403", "spread": "10.5975"}, {"groupId": "OG002", "value": "23.046", "spread": "8.6829"}, {"groupId": "OG003", "value": "21.037", "spread": "7.9355"}]}]}]}, {"type": "SECONDARY", "title": "Urine Sodium and Potassium Excretion Per Treatment at 8 Hours Postdose", "description": "Urine was collected 8 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 8 hours.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol", "timeFrame": "8 hours postdose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "Sodium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "129.990", "spread": "49.2835"}, {"groupId": "OG001", "value": "123.835", "spread": "56.2734"}, {"groupId": "OG002", "value": "125.677", "spread": "58.6125"}, {"groupId": "OG003", "value": "119.776", "spread": "59.0523"}]}]}, {"title": "Potassium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.474", "spread": "12.2417"}, {"groupId": "OG001", "value": "28.068", "spread": "12.5292"}, {"groupId": "OG002", "value": "36.120", "spread": "14.4509"}, {"groupId": "OG003", "value": "32.498", "spread": "9.6174"}]}]}]}, {"type": "SECONDARY", "title": "Urine Sodium and Potassium Excretion Per Treatment at 12 Hours Postdose", "description": "Urine was collected 12 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 12 hours.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol", "timeFrame": "12 hours postdose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "32"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "27"}]}], "classes": [{"title": "Sodium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "151.254", "spread": "57.6190"}, {"groupId": "OG001", "value": "142.476", "spread": "59.1617"}, {"groupId": "OG002", "value": "144.839", "spread": "63.6708"}, {"groupId": "OG003", "value": "140.887", "spread": "68.4341"}]}]}, {"title": "Potassium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "45.013", "spread": "17.3416"}, {"groupId": "OG001", "value": "37.827", "spread": "16.0087"}, {"groupId": "OG002", "value": "46.770", "spread": "17.4395"}, {"groupId": "OG003", "value": "44.137", "spread": "11.0631"}]}]}]}, {"type": "SECONDARY", "title": "Urine Sodium and Potassium Excretion Per Treatment at 24 Hours Postdose", "description": "Urine was collected 24 hours postdose in all treatment groups for sodium and potassium analysis. Each patient was required to void their bladder before drug administration and at the end 24 hours.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable pharmacodynamics (PD)data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol", "timeFrame": "24 hours postdose", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"title": "Sodium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "185.426", "spread": "69.9537"}, {"groupId": "OG001", "value": "187.256", "spread": "69.1028"}, {"groupId": "OG002", "value": "188.886", "spread": "73.8708"}, {"groupId": "OG003", "value": "192.176", "spread": "76.0983"}]}]}, {"title": "Potassium excretion", "categories": [{"measurements": [{"groupId": "OG000", "value": "57.323", "spread": "20.0607"}, {"groupId": "OG001", "value": "53.107", "spread": "21.3416"}, {"groupId": "OG002", "value": "62.715", "spread": "20.4014"}, {"groupId": "OG003", "value": "61.012", "spread": "13.6072"}]}]}]}, {"type": "SECONDARY", "title": "Mean Sitting Systolic Blood Pressure (msSBP)and Mean Sitting Diastolic Blood Pressure (msDBP)", "description": "Sitting blood pressure was measured three times at 1 to 2-minute intervals. The mean of the three sitting blood pressure measurements was used as the average of the sitting office blood pressure. The msSBP and msDBP data were analyzed using a mixed effect model with fixed effects from treatment and treatment\\*time; random effect from patients and predose as covariate.", "populationDescription": "Safety analysis set include subjects that received study drug.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmHg", "timeFrame": "0.5 hour pre-dose, 0.5, 1, 2, 4, 8, 12 and 24 hours post dose.", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG002", "title": "Furosemide go mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "32"}]}], "classes": [{"title": "0.5 predose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "118.26", "spread": "1.62"}, {"groupId": "OG001", "value": "117.09", "spread": "1.70"}, {"groupId": "OG002", "value": "116.63", "spread": "1.80"}]}]}, {"title": "0.5 hour predose (msDBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.70", "spread": "0.98"}, {"groupId": "OG001", "value": "71.41", "spread": "1.04"}, {"groupId": "OG002", "value": "71.39", "spread": "1.10"}]}]}, {"title": "0.5 hour Postdose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "114.78", "spread": "1.64"}, {"groupId": "OG001", "value": "113.19", "spread": "1.70"}, {"groupId": "OG002", "value": "114.31", "spread": "1.80"}]}]}, {"title": "0.5 hour Postdose (msDBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "70.94", "spread": "1.00"}, {"groupId": "OG001", "value": "69.04", "spread": "1.04"}, {"groupId": "OG002", "value": "69.86", "spread": "1.10"}]}]}, {"title": "1 hour Postdose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "115.15", "spread": "1.64"}, {"groupId": "OG001", "value": "112.22", "spread": "1.70"}, {"groupId": "OG002", "value": "112.16", "spread": "1.80"}]}]}, {"title": "1 hour Postdose (msDBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.22", "spread": "1.00"}, {"groupId": "OG001", "value": "69.04", "spread": "1.04"}, {"groupId": "OG002", "value": "68.96", "spread": "1.10"}]}]}, {"title": "2 hour Postdose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "113.61", "spread": "1.64"}, {"groupId": "OG001", "value": "109.22", "spread": "1.70"}, {"groupId": "OG002", "value": "109.63", "spread": "1.80"}]}]}, {"title": "2 hour Postdose (msDBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "68.39", "spread": "1.10"}, {"groupId": "OG001", "value": "67.50", "spread": "1.04"}, {"groupId": "OG002", "value": "68.39", "spread": "1.10"}]}]}, {"title": "4 hour Postdose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "106.50", "spread": "1.64"}, {"groupId": "OG001", "value": "101.84", "spread": "1.70"}, {"groupId": "OG002", "value": "101.06", "spread": "1.80"}]}]}, {"title": "4 hour Postdose (msDBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "63.85", "spread": "1.00"}, {"groupId": "OG001", "value": "62.32", "spread": "1.04"}, {"groupId": "OG002", "value": "59.07", "spread": "1.10"}]}]}, {"title": "8 hour Postdose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "110.75", "spread": "1.66"}, {"groupId": "OG001", "value": "112.09", "spread": "1.70"}, {"groupId": "OG002", "value": "109.95", "spread": "1.80"}]}]}, {"title": "8 hour Postdose (msDBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "66.33", "spread": "1.01"}, {"groupId": "OG001", "value": "66.94", "spread": "1.04"}, {"groupId": "OG002", "value": "66.46", "spread": "1.10"}]}]}, {"title": "12 hour Postdose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "116.99", "spread": "1.66"}, {"groupId": "OG001", "value": "116.90", "spread": "1.70"}, {"groupId": "OG002", "value": "115.16", "spread": "1.80"}]}]}, {"title": "12 hour Postdose (msdBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "67.86", "spread": "1.01"}, {"groupId": "OG001", "value": "68.79", "spread": "1.04"}, {"groupId": "OG002", "value": "68.50", "spread": "1.10"}]}]}, {"title": "24 hour Postdose (msSBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "115.49", "spread": "1.66"}, {"groupId": "OG001", "value": "116.69", "spread": "1.72"}, {"groupId": "OG002", "value": "118.41", "spread": "1.80"}]}]}, {"title": "24 hour Postdose (msDBP)", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.24", "spread": "1.01"}, {"groupId": "OG001", "value": "71.66", "spread": "1.05"}, {"groupId": "OG002", "value": "72.32", "spread": "1.10"}]}]}]}, {"type": "PRIMARY", "title": "Diuretic Efficacy Index 2 for Water Excretion", "description": "Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction urine collection.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/mg", "timeFrame": "0 to 4 hours", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "33"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "90.402", "spread": "34.7866"}, {"groupId": "OG001", "value": "109.773", "spread": "50.2433"}, {"groupId": "OG002", "value": "119.239", "spread": "63.3655"}, {"groupId": "OG003", "value": "122.157", "spread": "58.8815"}]}]}]}, {"type": "PRIMARY", "title": "Diuretic Efficacy Index 2 for Water Excretion", "description": "Efficacy of furosemide for water excretion (efficacy index 2) was defined by dividing urine volume by the urinary excretion of furosemide.Diuretic index 2 for water was calculated for the 0 to 4 hour fraction and for the total 0 to 24 hour urine collection.", "populationDescription": "All patients who received at least one dose of study drug and had evaluable PD data with no major protocol deviation in at least one period were included in the PD analysis set.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mL/mg", "timeFrame": "0 to 24 hours", "groups": [{"id": "OG000", "title": "Furosemide 60 mg + Aliskiren Placebo", "description": "Patient received 60 mg furosemide at steady state + placebo to aliskiren from day 1 to day 7."}, {"id": "OG001", "title": "Furosemide 60 mg + Single Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg on day 8."}, {"id": "OG002", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 150mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 150mg ( day 9 - day 17)."}, {"id": "OG003", "title": "Furosemide 60 mg + Multiple Dose Aliskiren 300mg", "description": "Patient received 60 mg furosemide at steady state + single dose aliskiren 300mg ( day 18 - day 27)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "30"}, {"groupId": "OG003", "value": "28"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "119.439", "spread": "46.2607"}, {"groupId": "OG001", "value": "151.859", "spread": "53.6734"}, {"groupId": "OG002", "value": "154.116", "spread": "40.5598"}, {"groupId": "OG003", "value": "175.112", "spread": "59.4236"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "60 mg Furosemide + 150 mg Placebo + 300 mg Placebo", "description": "60 mg furosemide + 150 mg placebo + 300 mg placebo", "seriousNumAffected": 2, "seriousNumAtRisk": 37, "otherNumAffected": 0, "otherNumAtRisk": 37}, {"id": "EG001", "title": "60 mg Furosemide + 150 mg Aliskiren + 300 mg Placebo", "description": "60 mg furosemide + 150 mg aliskiren + 300 mg placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 33, "otherNumAffected": 0, "otherNumAtRisk": 33}, {"id": "EG002", "title": "60 mg Furosemide + 300 mg Aliskiren + 150 mg Placebo", "description": "60 mg furosemide + 300 mg aliskiren + 150 mg placebo", "seriousNumAffected": 0, "seriousNumAtRisk": 31, "otherNumAffected": 0, "otherNumAtRisk": 31}], "seriousEvents": [{"term": "Rib fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Gout", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Haemothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}, {"term": "Pneumothorax", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 37}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 33}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 31}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000005665", "term": "Furosemide"}, {"id": "C000446481", "term": "Aliskiren"}], "ancestors": [{"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049994", "term": "Sodium Potassium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000092502", "term": "Renin Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M8784", "name": "Furosemide", "asFound": "48 hours", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M352589", "name": "Aliskiren", "asFound": "Distribution", "relevance": "HIGH"}, {"id": "M26153", "name": "Sodium Potassium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M2932", "name": "Renin Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}